The TWILIGHT trial indicates that switching to ticagrelor monotherapy after 3 months of dual antiplatelet therapy lowers the incidence of bleeding without increasing ischaemic events compared with continuation of ticagrelor plus aspirin therapy in patients who have undergone percutaneous coronary intervention and are at high risk of bleeding or ischaemic events

中文翻译：

---

替卡格雷单药治疗的黄金时间。

TWILIGHT试验表明，在接受经皮冠状动脉介入治疗且有较高出血或缺血风险的患者中，与继续使用替卡格雷或阿司匹林治疗相比，双重抗血小板治疗3个月后改用替卡格雷单药可降低出血发生率，而不会增加缺血事件大事记